Nomura Akihiro, Tada Hayato, Teramoto Ryota, Konno Tetsuo, Hodatsu Akihiko, Won Hong-Hee, Kathiresan Sekar, Ino Hidekazu, Fujino Noboru, Yamagishi Masakazu, Hayashi Kenshi
Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan; Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
J Cardiol. 2016 Feb;67(2):133-9. doi: 10.1016/j.jjcc.2015.09.003. Epub 2015 Oct 9.
The development of candidate gene approaches to enable molecular diagnosis of hypertrophic cardiomyopathy (HCM) has required extensive and prolonged efforts. Whole exome sequencing (WES) technologies have already accelerated genetic studies of Mendelian disorders, yielding approximately 30% diagnostic success. As a result, there is great interest in extending the use of WES to any of Mendelian diseases. This study investigated the potential of WES for molecular diagnosis of HCM.
WES was performed on seven relatives from a large HCM family with a clear HCM phenotype (five clinically affected and two unaffected) in the Kanazawa University Hypertrophic Cardiomyopathy Registry. Serial bioinformatics filtering methods as well as using combined annotation dependent depletion (CADD) score and high heart expression (HHE) gene data were applied to detect the causative variant. Moreover, additional carriers of the variant were investigated in the HCM registry, and clinical characteristics harboring the variant were collected and evaluated.
WES detected 60020 rare variants in the large HCM family. Of those, 3439 were missense, nonsense, splice-site, or frameshift variants. After genotype-phenotype matching, 13 putative variants remained. Using CADD score and HHE gene data, the number of candidates was reduced to one, a variant in the myosin essential light chain (MYL3, NM_000258.2:c.281G>A, p.Arg94His) that was shared by the five affected subjects. Additional screening of the HCM registry (n=600) identified two more subjects with this variant. Serial assessments of the variant carriers revealed the following phenotypic characteristics: (1) disease-penetrance of 88%; (2) all clinically affected carriers exhibited asymmetric septal hypertrophy with a substantial maximum left ventricular wall thickness of 18±3mm without any obstruction.
WES combined with CADD score and HHE gene data may be useful even in HCM. Furthermore, the MYL3 Arg94His variant was associated with high disease penetrance and substantial interventricular septal hypertrophy.
开发用于肥厚型心肌病(HCM)分子诊断的候选基因方法需要大量且长期的努力。全外显子测序(WES)技术已经加速了孟德尔疾病的基因研究,诊断成功率约为30%。因此,人们对将WES应用于任何孟德尔疾病都非常感兴趣。本研究调查了WES用于HCM分子诊断的潜力。
在金泽大学肥厚型心肌病登记处,对一个有明确HCM表型的大型HCM家族的七名亲属(五名临床受累者和两名未受累者)进行了WES。应用系列生物信息学筛选方法以及使用联合注释依赖缺失(CADD)评分和高心脏表达(HHE)基因数据来检测致病变异。此外,在HCM登记处对该变异的其他携带者进行了调查,并收集和评估了携带该变异的临床特征。
WES在这个大型HCM家族中检测到60020个罕见变异。其中,3439个是错义、无义、剪接位点或移码变异。经过基因型-表型匹配后,仍有13个推定变异。使用CADD评分和HHE基因数据,候选变异数量减少到一个,即肌球蛋白必需轻链(MYL3,NM_000258.2:c.281G>A,p.Arg94His)中的一个变异,该变异为五名受累受试者所共有。对HCM登记处(n = 600)的进一步筛查又发现了两名携带此变异的受试者。对变异携带者的系列评估揭示了以下表型特征:(1)疾病外显率为88%;(2)所有临床受累携带者均表现为不对称性室间隔肥厚,最大左心室壁厚度为18±3mm,无任何梗阻。
WES结合CADD评分和HHE基因数据在HCM中可能也有用。此外,MYL3 Arg94His变异与高疾病外显率和显著的室间隔肥厚有关。